ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.

T. Sievers, J. Thompson, J. Lake.

Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.

Meeting: 2016 American Transplant Congress

Abstract number: D293

Keywords: Hepatitis B, IVIG, Liver, Liver transplantation

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Viral Hepatitis

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.
  • Effective Long-Term Prophylaxis against De Novo Hepatitis B With Hepatitis B Vaccination in Pediatric Recipients of HbcAb-Positive Liver Grafts

Introduction

The hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide inhibitors and no hepatitis B immune globulin (HBIg) maintenance can yield equal or greater efficacy than indefinite HBIg in preventing recurrent hepatitis B after LTx.

Methods and Results

Charts of patients who received LTx at our institution for HBV-related liver complications (cirrhosis, HCC, acute liver failure) were reviewed and analyzed retrospectively. There were 45 patients included in this study who received limited HBIg prophylaxis and were maintained on nucleos(t)ide inhibitors long-term. Mean follow up time was 4.8 years post-transplant (range 0.2 to 11 years), during which three patients (6.7%) developed recurrence of HBV, which was defined by presence of HBV DNA or positive hepatitis B surface antigen (HBsAg). Two of those patients became HBsAg positive while remaining HBV DNA negative. The third patient with recurrence became HBV DNA positive while remaining HBsAg negative and was found to be non-compliant with medication and became HBV DNA negative again once tenofovir was resumed.

Discussion

Our HBV recurrence rate at the end of the study was 6.7%. However, one instance of recurrence in our study was related to medication non-compliance. Once this patient resumed tenofovir, the HBV DNA level became undetectable and has remained negative, now 9.4 years post LTx. The clinical impact of HBV recurrence in our study seems to be minimal. Two of the three patients with recurrence have maintained excellent liver function after a mean 6 years follow up since recurrence. Only one patient with HBsAg positivity required retransplantation due to biliary strictures, not HBV recurrence. This patient's course can be explained by the well-known complication of biliary strictures that occurs in deceased donor LTx.

Conclusion

Indefinite HBIg therapy adds significant expense to the prevention of HBV post-LTx. Our regimen of nucleo(t)side inhibitors with no HBIg maintenance presents a safe, efficacious and cost-effective means to prevent recurrence of post-liver transplant HBV.

CITATION INFORMATION: Sievers T, Thompson J, Lake J. Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sievers T, Thompson J, Lake J. Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/limited-hepatitis-b-immune-globulin-following-liver-transplant-for-hepatitis-b/. Accessed March 3, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.